Marcy l'Etoile, France - October 22, 2010. bioMérieux, a world leader in in vitro diagnostics, today released its business review for the nine months ended September 30, 2010.
- Nine-month sales up 4.3%* (5.5%* excluding the H1N1 impact)
- Continued deterioration of the healthcare environment in Western Europe and North America
- Very strong growth drivers*
- “Emerging 7” up 26%, excluding the H1N1 impact
- Clinical microbiology up 6.3%
- VIDAS® up 8.8%
- Industrial applications up 8%
- Confirmation of the 2010 target for operating margin before non-recurring items
Download
- Filename
- pr_biomerieux_q3_sales_2010_en26.pdf
- Size
- 103 KB
- Format
- application/pdf